Medtronic plc logo

Medtronic plc (4MDT)

Market Open
16 Jul, 15:30
XMIL XMIL
73. 20
+3.14
+4.4819%
- Market Cap
25.14 P/E Ratio
2.84% Div Yield
8 Volume
5.2 Eps
70.06
Previous Close
Add Transaction
Day Range
71.52 73.2
Year Range
64.06 90
Want to track 4MDT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

4MDT trading today higher at €73.2, an increase of 4.4819% from yesterday's close, completing a monthly increase of 3.6827% or €2.6. Over the past 12 months, 4MDT stock lost -12.0932%.
4MDT pays dividends to its shareholders, with the most recent payment made on Jul 17, 2026. The next estimated payment will be in In 2 months on Oct 17, 2026 for a total of €0.72.
The last earnings report, released on May 20, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.0267%, based on the last three reports.
Medtronic plc has completed 7 stock splits, with the recent split occurring on Sep 27, 1999.
The company's stock is traded on 14 different exchanges and in various currencies, with the primary listing on NYSE (USD).

4MDT Chart

Medtronic (MDT) Exceeds Market Returns: Some Facts to Consider

Medtronic (MDT) Exceeds Market Returns: Some Facts to Consider

Medtronic (MDT) reached $83.87 at the closing of the latest trading day, reflecting a +1.8% change compared to its last close.

Zacks | 1 week ago
Medtronic: Undervalued, And The Tailwinds Are Just Getting Started

Medtronic: Undervalued, And The Tailwinds Are Just Getting Started

I initiate coverage on Medtronic, highlighting its status as a leading medtech name with premium margins. MDT offers an attractive diversification opportunity, combining consistent performance with accelerated revenue growth. The stock trades at undervalued levels, supporting a long-term bullish thesis and a defensive investment approach.

Seekingalpha | 1 week ago
Medtronic: A Near Decade High Dividend For This Aristocrat

Medtronic: A Near Decade High Dividend For This Aristocrat

Medtronic is a dividend aristocrat with a near-decade high yield, making it an attractive long-term income opportunity. The company is experiencing strong revenue growth, driven by its leading positions in cardiovascular and neuroscience medical devices. While current free cash flow payout ratios are sustainable, investors should monitor future dividend growth rates closely.

Seekingalpha | 1 week ago

Medtronic plc (4MDT) FAQ

What is the stock price today?

The current price is €73.20.

On which exchange is it traded?

Medtronic plc is listed on XMIL.

What is its stock symbol?

The ticker symbol is 4MDT.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 2.84%.

What is its market cap?

As of today, no market cap data is available.

Has Medtronic plc ever had a stock split?

Medtronic plc had 7 splits and the recent split was on Sep 27, 1999.

Medtronic plc Profile

Health Care Equipment & Supplies Industry
Healthcare Sector
Geoffrey Straub Martha CEO
XMIL Exchange
IE00BTN1Y115 ISIN
IE Country
95,000 Employees
26 Jun 2026 Last Dividend
27 Sep 1999 Last Split
13 Jan 1978 IPO Date

Overview

Medtronic plc is a global leader in medical technology, specializing in the development, manufacture, and sale of device-based medical therapies. Serving healthcare systems, physicians, clinicians, and patients around the world, the company is dedicated to alleviating pain, restoring health, and extending life for millions of people. Founded in 1949 and headquartered in Dublin, Ireland, Medtronic operates across various medical domains through its diverse portfolio which includes cardiovascular, medical surgical, neuroscience, and diabetes treatments and technologies.

Products and Services

Medtronic’s comprehensive range of products and services is categorized into four primary segments:

  • Cardiovascular Portfolio: This segment offers advanced device-based solutions for cardiac care, including:
    • Implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices for heart rhythm management.
    • Cardiac ablation products for treating atrial fibrillation.
    • Insertable cardiac monitor systems for continuous heart monitoring.
    • TYRX products, which involve antimicrobial envelopes for electronic implantable devices.
    • Aortic valves, surgical valve replacement and repair products, transcatheter pulmonary valves, and endovascular stent grafts for structural heart disease treatment.
    • Percutaneous coronary intervention products and angioplasty balloons for coronary artery disease treatment.
    • Remote monitoring and patient-centered software for enhanced patient care.
  • Medical Surgical Portfolio: This segment encompasses a broad array of surgical instruments and devices, including:
    • Surgical stapling devices and vessel sealing instruments for precise surgical procedures.
    • Wound closure products and electrosurgery products aimed at efficient surgical recovery.
    • Surgical artificial intelligence and robotic-assisted surgery products for advanced surgical techniques.
    • Hernia mechanical devices and mesh implants, along with other gynecology and lung health products.
    • Minimally invasive gastrointestinal and hepatologic diagnostic and therapy tools, patient monitoring, airway management and ventilation therapies, and renal disease treatments.
  • Neuroscience Portfolio: This segment delivers solutions for the central nervous system and supportive structures, including:
    • Products for spinal, neuro, and orthopedic surgeries, pain management, and urology.
    • Energy surgery instruments and image-guided surgery systems for enhanced surgical accuracy.
    • Intra-operative imaging and robotic guidance systems for spine procedures.
    • Therapies for brain vasculature conditions.
  • Diabetes Operating Unit: Focused on diabetes management, this segment offers:
    • Insulin pumps and consumables for continuous insulin delivery.
    • Continuous glucose monitoring systems for real-time blood glucose tracking.
    • Smart insulin pen systems and related consumables for modern diabetes care.

Contact Information

Address: Building Two, Parkmore Business Park West
Phone: 353 1 438 1700